Home›Efavirenz Lamivudine And Tenofovir Disoproxil Fumarate›Efavirenz Lamivudine And Tenofovir Disoproxil Fumarate + Sofosbuvir

Does Efavirenz Lamivudine And Tenofovir Disoproxil Fumarate Interact with Sofosbuvir?

CDI records a moderate classification for Efavirenz Lamivudine And Tenofovir Disoproxil Fumarate and Sofosbuvir. The stored summary is: Velpatasvir/Sofosbuvir ↓ velpatasvir Coadministration of EFV and sofosbuvir/velpatasvir is not recommended because it may result in loss of therapeutic effect of sofosbuvir/velpatasvir. Velpatasvir/Sofosbuvir/ Voxilaprevir ↓ velpatasvir ↓ voxilaprevir Coadministration of EFV and sofosbuvir/velpatasvir/voxilaprevir is not recommended because it may result in loss of therapeutic effect of sofosbuvir/velpatasvir/voxilaprevir. Ledipasvir/Sofosbuvir ↑ TDF Monitor for adverse reactions associated with TDF. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.

Evidence status

A current label comparison is not yet available for this record. The summary and severity are stored CDI information; they have not been independently validated on this page against the exact product label.

Confirm the medicine, formulation, route, and applicable warning with your pharmacist or prescriber. Independent clinical review has not been recorded.

Stored CDI classification
Moderate
Efavirenz Lamivudine And Tenofovir Disoproxil Fumarate Class
Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor
Sofosbuvir Class
Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor
Management
Confirm exact products with your pharmacist
Data Source
U.S. FDA via OpenFDA

What To Tell Your Doctor or Pharmacist

If you are taking Efavirenz Lamivudine And Tenofovir Disoproxil Fumarate and your doctor is considering prescribing Sofosbuvir (or vice versa), make sure to:

  • Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
  • Ask whether the benefits of combining these medications outweigh the risks for your specific situation
  • Ask what symptoms to watch for that would indicate the interaction is causing problems
  • Ask whether any dosage adjustments are needed
  • Never stop or change either medication without first consulting your healthcare provider
💊 Efavirenz Lamivudine And Tenofovir Disoproxil Fumarate(Symfi)+💊 Sofosbuvir(Sovaldi)

Severity & Interaction Details

🟡
moderate
Stored CDI classification: moderate
A current source comparison has not been recorded for this claim. The stored classification does not determine the clinical significance for your exact products or circumstances.
Severity scale
MinorContra
On record
Yes
Drug A class
Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor
Drug B class
Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor
Source
FDA drug label - efavirenz, lamivudine and tenofovir disoproxil fumarate

What this means in plain English

Velpatasvir/Sofosbuvir ↓ velpatasvir Coadministration of EFV and sofosbuvir/velpatasvir is not recommended because it may result in loss of therapeutic effect of sofosbuvir/velpatasvir. Velpatasvir/Sofosbuvir/ Voxilaprevir ↓ velpatasvir ↓ voxilaprevir Coadministration of EFV and sofosbuvir/velpatasvir/voxilaprevir is not recommended because it may result in loss of therapeutic effect of sofosbuvir/velpatasvir/voxilaprevir. Ledipasvir/Sofosbuvir ↑ TDF Monitor for adverse reactions associated with TDF.

About Efavirenz Lamivudine And Tenofovir Disoproxil Fumarate and Sofosbuvir

Efavirenz Lamivudine And Tenofovir Disoproxil Fumarate is a Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor, while Sofosbuvir is a Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor. You may recognize them by the brand names Symfi and Sovaldi. Both Efavirenz Lamivudine And Tenofovir Disoproxil Fumarate and Sofosbuvir carry an FDA boxed warning — the agency's most serious safety designation.

Source and Limitations

This record was produced by automated extraction from drug-label information, including AI processing. The summary and mechanism are not verbatim FDA quotations. The drug profiles below may describe different formulations from the source label. Confirm the exact product and route with your pharmacist. This page does not establish independent clinical review.

📖 Source: FDA drug label - efavirenz, lamivudine and tenofovir disoproxil fumarate

Recent research & FDA safety updates

Live

Auto-aggregated from PubMed E-utilities and FDA safety data.

Share this result:

WhatsAppText / SMSEmail
Also share on:XFacebook
Add more drugs
Check Efavirenz Lamivudine And Tenofovir Disoproxil Fumarate and Sofosbuvir against your full medication list

Most patients take more than two medications. CDI checks every pair across up to 20 drugs simultaneously — including OTCs and common supplements.

Add more drugs →
How this information is prepared: CDI uses automated extraction, including AI, to summarize drug labeling from openFDA and includes separately identified curated-reference records. RxNorm helps identify medications; it does not verify interaction claims. Extracted summaries and CDI severity classifications can contain errors and are not verbatim FDA statements or independent clinical review. Maintained by CheckDrugInteractions.com. See our methodology or report a correction at support@checkdruginteractions.com.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine, supplemented with a small number of well-established interactions from curated clinical references. For informational purposes only. Always consult your pharmacist or physician.

CDI: source-linked explanations